URGENT ALERT: Please beware of fraudulent WhatsApp groups and other groups across Social Media pretending to be affiliated with Anchor and Anchor staff members. Do not engage with these malicious and fraudulent groups in any way. Please direct all queries to invest@anchorcapital.co.za.

Johnson & Johnson posts strong results, raises guidance

Biotech and healthcare company, Johnson & Johnson (JNJ) posted 3Q18 results on Tuesday (16 October), with revenue standing at $20.35bn (+3% YoY) compared with $19.65bn posted in 3Q17, while diluted EPS came in at $2.05 vs $1.90 recorded in 3Q17. Thomson Reuters consensus forecasts had expected EPS of $2.03 on revenue of $20.5bn.

The slightly better-than-expected 3Q profit and the firm raising its full-year guidance was on the back of strong sales of its cancer drugs and immune disorder treatments, which powered strong results for its pharmaceutical unit. A turnaround in its baby care business also helped the firm outpace 3Q18 earnings and revenue estimates.

In terms of segments, JNJ’s pharmaceuticals business posted $10.35bn (+6.7% YoY) in revenue, beating Thomson Reuters consensus estimates of $10.02bn. Meanwhile, its medical device sales totaled $6.59bn (-0.2% YoY and missing expectations of $6.64bn), while the consumer business posted $3.42bn (+1.8% YoY) in sales – above the $3.34bn consensus forecasts had anticipated.

In the quarter under review, global sales of JNJ’s cancer drug Darzalex reached $498mn, missing analysts’ estimates of $510mn, while sales of Stelara, an immunotherapy treatment for plaque psoriasis, reached $1.31bn (+16.5% YoY), exceeding analysts’ expectations of $911mn. Prostate cancer drug, Zytiga sales surged 43% YoY to $958mn – significantly above the consensus estimate of $795mn. However, sales of its blockbuster arthritis drug Remicade fell 16.3% YoY to $1.38bn due to increasing competition from cheaper biosimilar versions.

Reuters reports that, according to the company, pricing pressure impacted all categories in orthopedics. JNJ added that “it will consider both transformative acquisitions and smaller, tuck-in deals to support the business.” The company has been selling off certain businesses (such as its diabetes care devices), to focus on better-performing units and the development of new products.

Looking ahead, for FY18, JNJ raised its earnings and revenue guidance saying that it now expects EPS to be between $8.13 and $8.18 (+9.3% to 10.0%), with revenue forecast to be in the range of $81.0bn to $81.4bn. Its previous guidance was for FY18 revenue of $80.5bn-$81.3bn.



Submit your details and we’ll give you a call back to assist and advise you on your investment.


Subscribe to our newsletters to receive regular market commentary, research and updates from the Anchor team. Select between our Individual or Financial Advisor newsletters by selecting the relevant tab below.

WEBINAR | The Navigator – Anchor’s Strategy and Asset Allocation, 2Q24

Anchor CEO and Co-CIO Peter Armitage will host the webinar, provide an introduction to current global and local market conditions and give his thoughts on offshore equities. Together with Head of Fixed Income and Co-CIO Nolan Wapenaar, Pete will also discuss Anchor’s strategy and asset allocation for 2Q24, focusing on global equities and bonds. In addition, Fund Manager Liam Hechter will provide insights into local equities, highlighting some investment ideas; Global Equities Analyst James Bennet will discuss Ferrari and give an update on Tesla, and finally, Analyst Thomas Hendricks will participate in a Q&A with Peter, explaining the 10-year US Treasury to attendees.